We in silico analyzed the essentiality of PTK2 for the growth of KRAS mutation‐dependent cell lines identified by Achilles’ project (Figure S2A, Supporting Information).[22] Analysis of data for shRNA modulated PTK2 knockdown showed that, unlike any of the KRAS wild‐type cancer cell lines, all of the KRAS‐mutant‐dependent cell lines exhibited growth modulation related to PTK2 expression (Figure S2B, Supporting Information). The gene discussed is PTK2; the disease is cancer.